Status:

RECRUITING

Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH)

Lead Sponsor:

Montefiore Medical Center

Collaborating Sponsors:

Geisinger Clinic

Heidelberg University

Conditions:

Chronic Subdural Hematoma

Eligibility:

All Genders

18+ years

Brief Summary

This multi-center retrospective cohort study aims to investigate the real-world outcomes of chronic subdural hematoma treated with MMAE, including clinical effectiveness, recurrence rates, and safety ...

Detailed Description

Chronic subdural hematoma (cSDH) is a prevalent neurosurgical condition marked by the accumulation of blood in the subarachnoid space. Primarily affecting elderly individuals, cSDH is associated with ...

Eligibility Criteria

Inclusion

  • Consecutive adult patients (18 yrs. of age or older)
  • Endovascular embolization of middle meningeal artery using any embolization material:
  • PVA particles; Onyx, nBCA glue; dimethyl sulfoxide, microcoils, PVA with microcoils

Exclusion

  • Endovascular embolization of middle meningeal artery using any other embolization material

Key Trial Info

Start Date :

December 5 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

August 1 2026

Estimated Enrollment :

5000 Patients enrolled

Trial Details

Trial ID

NCT06181994

Start Date

December 5 2023

End Date

August 1 2026

Last Update

January 7 2026

Active Locations (19)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 5 (19 locations)

1

Baptist Health South Florida, Inc.

Coral Gables, Florida, United States, 33143

2

Mayo Clinic Florida

Jacksonville, Florida, United States, 32224

3

Orlando Regional Medical Center

Orlando, Florida, United States, 32806

4

University of Illinois Chicago

Chicago, Illinois, United States, 60607

Middle Meningeal Artery Embolization (MMAE) Outcomes for Chronic Subdural Hematoma (cSDH) | DecenTrialz